"Ocugen Completes Dosing for Stargardt Clinical Trial Phase 1/2"
Ocugen, Inc. has completed dosing in the first cohort of its Phase 1/2 GARDian clinical trial for OCU410ST, a potential gene therapy for Stargardt disease, a genetic eye disorder causing retinal degeneration and vision loss. The trial aims to assess the safety and efficacy of OCU410ST, which utilizes an AAV delivery platform for retinal delivery of the RORA gene. The company's Chief Scientific Officer, Dr. Arun Upadhyay, highlighted the significance of this milestone in providing hope for patients with Stargardt disease, for which there is currently no treatment option available.